Identification of kinase inhibitors that target transcription initiation by RNA polymerase II

Oncotarget

Volumn 2, Issue 1-2, 2011, Pages 18-28

  Morachis, José M ^a,b   Huang, Ruo ^a   Emerson, Beverly M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Core promoters; Fas APO1; Kinase inhibitors; P21; P53; RNA polymerase II; Transcription therapy

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; HYPERICIN; RNA POLYMERASE II; ROTTLERIN; TATA BINDING PROTEIN; PROTEIN KINASE INHIBITOR;

ARTICLE; CONCENTRATION RESPONSE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG TARGETING; ENZYME SPECIFICITY; IN VITRO STUDY; PROMOTER REGION; RNA SYNTHESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; HUMAN; METABOLISM;

DRUG EVALUATION, PRECLINICAL; HELA CELLS; HUMANS; PROTEIN KINASE INHIBITORS; RNA POLYMERASE II; TATA-BOX BINDING PROTEIN; TRANSCRIPTION, GENETIC;

EID: 79960880160     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.212     Document Type: Article

References (40)

1. Juven-Gershon T, Hsu JY, Theisen JW, Kadonaga JT. The RNA polymerase II core promoter - the gateway to transcription. Curr Opin Cell Biol 2008, 20(3), 253-259.
2. Juven-Gershon T, Kadonaga JT. Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev Biol 2010, 339(2), 225-229.
3. Palancade B, Bensaude O. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 2003, 270(19), 3859-3870.
4. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets, 11(3), 291-302.
5. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999, 97(1), 41-51.
6. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010, 11(3), 291-302.
7. Dai Y, Grant S. Small molecule inhibitors targeting cyclindependent kinases as anticancer agents. Curr Oncol Rep 2004, 6(2), 123-130.
8. De Azevedo WF, Jr., Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structuralbasis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 1996, 93(7), 2735-2740.
9. Pippin JW, Qu Q, Meijer L, Shankland SJ, Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997, 100(10), 2512-2520.
10. Blagosklonny MV. Flavopiridol, an inhibitor of transcription, implications, problems and solutions. Cell Cycle 2004, 3(12), 1537-1542.
11. Ljungman M, Lane DP. Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer 2004, 4(9), 727-737.
12. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999, 18(3), 583-592.
13. Derheimer FA, Chang CW, Ljungman M. Transcription inhibition, a potential strategy for cancer therapeutics. Eur J Cancer 2005, 41(16), 2569-2576.
14. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004, 64(10), 3653-3660.
15. Sausville EA. Cell cycle regulatory kinase modulators, interim progress and issues. Curr Top Med Chem 2005, 5(12), 1109-1117.
16. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005, 63, 183-206.
17. Bushnell DA, Cramer P, Kornberg RD. Structural basis of transcription, alpha-amanitin-RNA polymerase II cocrystal at 2.8 A resolution. Proc Natl Acad Sci U S A 2002, 99(3), 1218-1222.
18. Kadam S, McAlpine GS, Phelan ML, Kingston RE, Jones KA, Emerson BM, Functional selectivity of recombinant mammalian SWI/SNF subunits. Genes Dev 2000, 14(19), 2441-2451.
19. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001, 276(34), 31793-31799.
20. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998, 188(11), 2033-2045.
21. Abbas T, Dutta A, p21 in cancer, intricate networks and multiple activities. Nat Rev Cancer 2009, 9(6), 400-414.
22. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4), 817-825.
23. Morachis JM, Murawsky CM, Emerson BM. Regulation ofthe p53 transcriptional response by structurally diverse core promoters. Genes Dev 2010, 24(2), 135-147.
24. Juven-Gershon T, Cheng S, Kadonaga JT. Rational design of a super core promoter that enhances gene expression. Nat Methods 2006, 3(11), 917-922.
25. de Witte P, Agostinis P, Van Lint J, Merlevede W, Vandenheede JR. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem Pharmacol 1993, 46(11), 1929-1936.
26. Tang J, Colacino JM, Larsen SH, Spitzer W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antiviral Res 1990, 13(6), 313-325.
27. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010, 11(2), 562-594.
28. Ritz R, Wein HT, Dietz K, Schenk M, Roser F, Tatagiba M, Strauss WS. Photodynamic therapy of malignant glioma with hypericin, comprehensive in vitro study in human glioblastoma cell lines. Int J Oncol 2007, 30(3), 659-667.
29. Miskovsky P. Hypericin-a new antiviral and antitumor photosensitizer, mechanism of action and interaction with biological macromolecules. Curr Drug Targets 2002, 3(1), 55-84.
30. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351(Pt 1), 95-105.
31. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994, 199(1), 93-98.
32. Soltoff SP. Rottlerin, an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 2007, 28(9), 453-458.
33. Susarla BT, Robinson MB. Rottlerin, an inhibitor of protein kinase Cdelta (PKCdelta), inhibits astrocytic glutamate transport activity and reduces GLAST immunoreactivity by a mechanism that appears to be PKCdelta-independent. J Neurochem 2003, 86(3), 635-645.
34. Gertsch J, Guttinger M, Sticher O, Heilmann J. Relative quantification of mRNA levels in Jurkat T cells with RTreal time-PCR (RT-rt-PCR), new possibilities for the screening of anti-inflammatory and cytotoxic compounds. Pharm Res 2002, 19(8), 1236-1243.
35. Nieminen R, Lahti A, Jalonen U, Kankaanranta H, Moilanen E. JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages. Int Immunopharmacol 2006, 6(6), 987-996.
36. Maldonado E, Allende JE. Phosphorylation of yeast TBP by protein kinase CK2 reduces its specific binding to DNA. FEBS Lett 1999, 443(3), 256-260.
37. Chibazakura T, Watanabe F, Kitajima S, Tsukada K, Yasukochi Y, Teraoka H. Phosphorylation of human general transcription factors TATA-binding protein and transcription factor IIB by DNA-dependent protein kinase-synergistic stimulation of RNA polymerase II basaltranscription in vitro. Eur J Biochem 1997, 247(3), 1166-1173.
38. Wang Y, Fairley JA, Roberts SG. Phosphorylation of TFIIB links transcription initiation and termination. Curr Biol 2010, 20(6), 548-553.
39. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and sitedirected cofactor recruitment. Mol Cell 2001, 8(1), 57-69.
40. Lusser A, Kadonaga JT. Strategies for the reconstitution of chromatin. Nat Methods 2004, 1(1), 19-26.